Bio-Thera's New ADC Aims to Disarm Cancer's Defenses in Phase 1 Trial

GUANGZHOU, China – July 23, 2026 – Bio-Thera Solutions, a biopharmaceutical company rapidly ascending from a biosimilar powerhouse to a global innovator, announced today it has dosed the first patient in a Phase 1 clinical study for BAT8013. The candidate is a sophisticated antibody-drug conjugate (ADC) designed to dismantle the protective shield around solid tumors, potentially unlocking the power of the immune system for patients with advanced cancers.

The multicenter, open-label study marks a critical milestone for the company and its expanding oncology pipeline. It will assess the safety, tolerability, and optimal dosing of BAT8013 in patients with advanced solid tumors, a population with significant unmet medical needs. While early-stage, the trial represents a calculated move into one of modern oncology's most promising frontiers: modulating the tumor microenvironment to make cancers vulnerable to attack.

A Precision Strike on Cancer's Immune Shield

At the heart of BAT8013's strategy is a specific target: the CD25 protein. This protein, also known as the interleukin-2 receptor alpha chain (IL-2Rα), is found in high concentrations on the surface of regulatory T cells, or Tregs. In a healthy body, Tregs act as peacekeepers, preventing the immune system from overreacting. In the context of cancer, however, they are co-opted by tumors, forming a dense, immunosuppressive barrier that shields cancer cells from the body's natural defenses.

"Tregs effectively act as bodyguards for the tumor, telling would-be attacker cells to stand down," explained an immunologist not affiliated with the study. "By removing them, you can theoretically take the brakes off the immune system."

BAT8013 is engineered to do just that. As an ADC, it combines the precision of a monoclonal antibody with the power of a cytotoxic payload. The antibody component seeks out and binds to CD25-expressing Tregs within the tumor microenvironment. Once attached, the entire complex is internalized by the Treg. Inside the cell, a proprietary, cleavable linker releases a potent topoisomerase I inhibitor payload, killing the immunosuppressive cell from within.

What makes Bio-Thera's approach particularly compelling is the design of its payload. The small molecule inhibitor has strong cell membrane penetration, enabling a powerful 'bystander effect.' When a targeted Treg is destroyed, the released payload can seep out and kill nearby Tregs and potentially even tumor cells that don't express CD25. This collateral damage is a strategic advantage, helping to overcome tumor heterogeneity and more thoroughly dismantle the tumor's defensive network.

Furthermore, preclinical studies have shown that BAT8013 works synergistically with PD-1 inhibitors, the current standard of care in immuno-oncology. By depleting the Treg population, BAT8013 is expected to make the tumor microenvironment more receptive to the effects of checkpoint inhibitors like Bio-Thera's own PD-1 candidate, BAT1308, potentially turning non-responders into responders.

Navigating a Crowded Field with Next-Gen Technology

The ADC market is a fiercely competitive arena, with established giants like Pfizer (via its Seagen acquisition), Daiichi Sankyo, and AstraZeneca dominating the landscape. To carve out a niche, newcomers must bring genuinely differentiated technology to the table. Bio-Thera believes its proprietary ADC platform gives BAT8013 that edge and supports its claim as a potential 'best-in-class' therapy.

The key challenge in targeting CD25 has always been selectivity. Since CD25 is also expressed on activated effector T cells—the very cells needed to kill cancer—a poorly designed therapy could inadvertently weaken the desired immune response. Bio-Thera's approach, leveraging a stable linker that minimizes payload release in the bloodstream and a payload that creates a localized bystander effect within the tumor, is engineered to mitigate this risk.

"The success of any Treg-depleting strategy hinges on its precision within the tumor microenvironment," noted a market analyst covering the ADC space. "If the preclinical data on stability and the bystander effect translate to the clinic, it could represent a significant step forward for this class of drugs."

BAT8013 is not an isolated effort but the cornerstone of a broader, deliberate strategy. The Guangzhou-based company is building a formidable ADC pipeline, with other candidates targeting well-validated oncology markers like Folate Receptor alpha (BAT8006), Trop2 (BAT8008), Her2 (BAT8010), and B7-H3 (BAT8009). This multi-pronged approach diversifies risk and showcases the versatility of its next-generation ADC platform, which underpins several of these programs.

From Biosimilars to Bio-Innovation: Bio-Thera's Strategic Pivot

Bio-Thera's journey into cutting-edge oncology innovation is funded by a highly successful commercial business. The company has skillfully navigated complex global regulatory pathways to launch a portfolio of six approved products, primarily biosimilars of blockbuster drugs like Humira (adalimumab), Stelara (ustekinumab), and Avastin (bevacizumab).

These products, including TOFIDENCE® (tocilizumab) and AVZIVI® (bevacizumab-tnjn) in the US and EU, generate a steady revenue stream that fuels the company's ambitious R&D engine. This dual strategy of commercial execution and forward-looking innovation has allowed Bio-Thera to evolve from a follower into a leader, becoming one of a growing cohort of Chinese biopharmaceutical firms making significant contributions to global drug development.

With more than 20 promising candidates in its clinical pipeline, the company's focus is squarely on the future of oncology. This includes not only its ADC platform but also novel immuno-oncology assets like bispecific antibodies designed to deliver a one-two punch to tumors. The initiation of the BAT8013 trial is a clear signal of the company's confidence in its internal discovery capabilities and its ambition to compete on the world stage.

Redefining Hope for Advanced Solid Tumors

For patients with advanced solid tumors, the promise of immunotherapy has been a beacon of hope. Yet, for many, immune checkpoint inhibitors alone are not enough. Resistance, either primary or acquired, remains a major hurdle, leaving a large population with limited options.

Therapies like BAT8013 that aim to fundamentally re-engineer the tumor microenvironment could be the key to overcoming this resistance. By eliminating the immunosuppressive Tregs, BAT8013 could potentially broaden the umbrella of patients who can benefit from existing immunotherapies, offering a new combination strategy for some of the most difficult-to-treat cancers.

The Phase 1 trial will be the first test of this hypothesis in humans. Investigators will carefully monitor patients to establish a safe and effective dose, while also looking for preliminary signs of anti-tumor activity and changes in the immune landscape. The journey through clinical development is long and fraught with uncertainty, but for patients and physicians seeking new ways to fight advanced cancer, the start of this trial represents a meaningful step forward.